New Zealand markets closed

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2500-0.0400 (-3.10%)
At close: 04:00PM EST
1.2500 0.00 (0.00%)
Pre-market: 04:15AM EST

Ocugen, Inc.

263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
484 328 4701

Full-time employees56

Key executives

NameTitlePayExercisedYear born
Dr. Shankar Musunuri M.B.A., MBA, Ph.D.Co-Founder, Chairman & CEO845.2k6.67M1964
Dr. Uday B. Kompella Ph.D.Co-founder & Independent Director44kN/A1967
Ms. Jessica Crespo CPA, CPAChief Accounting Officer, Sr. VP of Fin. and VP of Corp. Controller & TreasurerN/AN/A1977
Dr. Arun Upadhyay Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Tiffany Hamilton M.B.A.Head of Corp. CommunicationsN/AN/AN/A
Ms. Zara GaudiosoAVP, Head of HR & Chief of StaffN/AN/AN/A
Mr. Michael ShineSr. VP of CommercialN/AN/AN/A
Dr. Robert J. Hopkins FACP, M.D., M.P.H.Chief Medical OfficerN/AN/AN/A
Mr. Quan Anh VuChief Bus. OfficerN/AN/A1973
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Corporate governance

Ocugen, Inc.’s ISS governance QualityScore as of 1 February 2023 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.